Overview

This book provides updated findings and trends of hereditary breast and ovarian cancer (HBOC) research and clinical practice, offering a comprehensive overview of the latest advancement. It captures the dynamic changes in HBOC treatment, driven by innovations such as poly (ADP-ribose) polymerase inhibitors and BRCA1/2 genetic testing. Key concepts explored include the DNA damage response, precision cancer medicine, and the challenges of regional cooperation in clinical practice. The book also addresses critical issues like homologous recombination deficiency (HRD) testing and the ethical considerations of preimplantation genetic testing. Contributions from leading experts provide insights into the latest evidence and trends, making this book an essential resource for understanding the evolving landscape of HBOC management. Practical Guide to Hereditary Breast and Ovarian Cancer IV - Annual Meeting of the JOHBOC is written by the authors of the best-chosen works presented at the 4th Annual Meeting in 2024. Designed for breast surgeons, gynecologists, geneticists, and medical staff involved in HBOC practice, this book is also valuable for HBOC patients and their families. With its focus on the latest research and clinical applications, this volume is an indispensable guide for anyone seeking to stay informed about the current state and future directions of HBOC treatment in Japan and the world.

Full Product Details

Author:   Masami Arai ,  Shinji Ohno ,  Masayuki Sekine
Publisher:   Springer Verlag, Singapore
Imprint:   Springer Verlag, Singapore
ISBN:  

9789819565795

ISBN 10:   9819565790
Pages:   227
Publication Date:   29 March 2026
Audience:   College/higher education ,  Professional and scholarly ,  Postgraduate, Research & Scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Forthcoming
Availability:   Not yet available  
This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release.

Table of Contents

Part I Advances in Basic Science.- 1. DNA damage response and Immune checkpoint: Recent advances in basic science.- 2. Tissue-specific carcinogenesis induced by BRCA1 deficiency.- Part II Advances in Genetics.- 3. RCA1/2 pathogenic variant-based precision cancer medicine-Insights from C-CAT real world data.- 4. Translating moderate-risk gene data into clinical practice: Focus on CHEK2 germline pathogenic variants.- 5. Large scale functional analysis and evaluation of pathogenicity in BRCA2.- 6. Integrating BRCA1 and BRCA2 pathogenic variants with polygenic risk scores.- Part III Advances in Breast Cancer.- 7. Supporting strategies for HBOC unaffected carriers.- 8. Clinical Practice for Unaffected pathogenic variant carriers of BRCA1/2.- 9. Issue in unaffected carriers from the surveillance out-patients viewpoint.- 10. Present status of clinical practice for HBOC carriers without ovarian cancer.- Part IV Equalization and regional cooperation of clinical practice for hereditary tumor.- 11. Proliferation and regional cooperation in HBOC clinical practice.- 12. Regional cooperation and Equalization in Clinical Practice for hereditary tumor syndrome.- 13. Present status and issue of cooperation of HBOC Clinical Practice in Niigata Prefecture.- 14. Equalization and regional cooperation of clinical practice for hereditary tumor from public data.- 15. Expanding Opportunities and Evolving Challenges in the Genetic Diagnosis and Genetic Counseling of Hereditary Tumors in Japan.- Part V Update on evaluation of homologous recombination deficiency (HRD).- 16. Current Status and Problems of HRD Testing in Ovarian Cancer Treatment.- 17. Timing and Cutoff Line of My Choice HRD Test.- 18. A review of pathological classification by artificial intelligence: a challenge to HRD diagnosis.- Part VI Advances in Assisted Reproductive Technology and PGT-M.- 19. Update on Reproductive Medicine for HBOC.- 20. Progress of Discussion on Indications for PGT in Japan.- Part VII Excellent general presentation.- 21. Knock-in rat model of the BRCA1 pathogenic variant L63X: its basic phenotypes and perspectives for use in cancer prevention research.- 22. BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer.- 23. BRCA2 c.7847C>T (p.Ser2616Phe): A Pathogenic Variant Specific to the Japanese Population.- 24. Prevalence and characteristics of pathogenic variants in BRCA1/2 genes in the Japanese population.- Part VIII JOHBOC registration.- 25. JOHBOC Registration, Registration data of JOHBOC 2023.

Reviews

Author Information

Masami Arai Masami Arai, MD, graduated from the Department of Medicine at Kagoshima University in 1986. He specializes in clinical genetic medicine for hereditary cancers, such as HBOC, and has worked at the Cancer Institute Hospital (January 2000–March 2018) and Juntendo University (April 2018–present). From 2014 to 2016, he led the Health Labour Sciences Research Grant Research Group on HBOC. During this period, he published the Guidebook for Diagnosis and Treatment of HBOC 2017, which established Japan’s first clinical management guidelines for HBOC. At the same time, he contributed to the development of a nationwide registration system for BRCA1/2 mutation carriers. Currently, he serves as Professor in the Department of Clinical Genetics at Juntendo University and also oversees the institution’s genetic counseling course. Shinji Ohno Dr Ohno is the Chairman of Japanese Organization of Hereditary Breast and Ovarian Cancer (JOHBOC).  After postgraduate training at Kyushu University since 1984, he spent three years as a research fellow in the Department of Surgery II at Kyushu University since 1986 and another two years in Internal Medicine at the University of Texas Medical School, U.S.A. since 1989. Then assumed a position as Assistant Professor of the Department of Surgery II at Kyushu University between 1993 and 2000. Was the Director of the Department of Breast Oncology at the National Kyushu Cancer Center from 2000 to 2015.  Since then, he has been Center Chief of Breast Oncology, and Deputy director of Cancer Institute Hospital in Tokyo.  Since 1st September 2023, he has been the director of Sagara Hospital.  Internationally, is a faculty of Advanced Breast Cancer International Consensus Conference,  a member of the Guideline Committee of European Society for Medical Oncology, and an International Advisory Member of The Breast, and a Faculty of American College of Surgeon. Masayuki Sekine Department of Obstetrics and Gynecology Graduate School of Medical Science, University of the Ryukyu Education:  2002; Ph.D. Niigata University Graduate School of Medical and Dental Sciences 1994; Graduated, Faculty of Medicine, Niigata University Professional Experience: 2023 – Present; Professor and Chairman, Department of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus 2015 – 2023;  Associate Professor, Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences 2013 – 2015;  Assistant Professor, Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences 2010 – 2013;  Chief Gynecologist, Nagaoka Red Cross Hospital 2006 – 2010;  Assistant Professor, Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences 2005 – 2006;  Visiting Fellow, Harvard Institute of Medicine 2002 – 2005;  Assistant Professor, Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences 1998 – 2002;  Graduate Student, Niigata University Graduate School of Medical and Dental Sciences 1997 – 1998;  Resident, Niigata City General Hospital 1996 – 1997;  Resident, Akita Red Cross Hospital 1995 – 1996;  Resident, Saiseikai Kawaguchi General Hospital 1994 – 1995;  Resident, Department of Obstetrics and Gynecology, Niigata University Medical and Dental Hospital.

Tab Content 6

Author Website:  

Countries Available

All regions